Seeking Alpha

Leerink initiates Acceleron Pharma at Outperform, sees 50% upside

  • Leerink starts Acceleron Pharma (XLRN -0.3%) at Outperform.
  • The company is "pushing innovation boundaries with lead compounds for anemia (Sotatercept, ACE-536) and oncology (Dalantercept)," analyst Marko Kozul says.
  • Leerink thinks Sotatercept and ACE-536 "have potential to compete directly with ESAs" such as Aranesp and Epogen (AMGN) and Procrit (JNJ).
  • As for Dalantercept (ACE-041), Kozul says it "could be used synergistically with any VEGF-inhibitor."
  • Finally, Kozul says XLRN "has important catalysts for almost every quarter through YE14."
  • Price target is set at $33.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector